Enzo Biochem and the Spinal Muscular Atrophy (SMA) Foundation reported that Enzo's wholly owned subsidiary, Enzo Life Sciences, has launched an immunoassay (ELISA) system which can be used for the identification and detection of Survival Motor Neuron (SMN) protein.

The kit is the result of a collaborative agreement between Enzo and the SMA Foundation for the development of reagents and assays for SMN protein.

The availability of an effective SMN ELISA could further enable and expedite drug discovery, development and therapy for Spinal Muscular Atrophy, the leading genetic cause of mortality in infants and toddlers.

The Enzo SMN ELISA Kit provides a reliable and widely-accessible means for researchers to measure SMN protein levels, and greatly simplifies and accelerates efficacy assessment of potential drugs in clinical trials that are designed to increase SMN protein levels.

The assay has been validated for use with human and mouse cell lysates and tissue homogenates, such as peripheral blood mononuclear cell (PBMC) lysates, and will be marketed through Enzo’s worldwide sales and marketing group.